CPEX = Verdammt billig und so gut wie Unbekannt !!!!!!! - 500 Beiträge pro Seite
eröffnet am 04.11.09 19:45:29 von
neuester Beitrag 02.12.09 20:12:48 von
neuester Beitrag 02.12.09 20:12:48 von
Beiträge: 19
ID: 1.154.064
ID: 1.154.064
Aufrufe heute: 0
Gesamt: 968
Gesamt: 968
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 33 Minuten | 23640 | |
| vor 48 Minuten | 4225 | |
| vor 28 Minuten | 4069 | |
| vor 21 Minuten | 3325 | |
| vor 38 Minuten | 2085 | |
| vor 53 Minuten | 1841 | |
| vor 1 Stunde | 1632 | |
| vor 9 Minuten | 1238 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.113,55 | -0,27 | 215 | |||
| 2. | 2. | 160,87 | +11,19 | 196 | |||
| 3. | 8. | 9,6450 | -33,53 | 192 | |||
| 4. | 3. | 0,1915 | +0,26 | 59 | |||
| 5. | 9. | 761,23 | -0,08 | 36 | |||
| 6. | 19. | 6,7580 | -2,26 | 28 | |||
| 7. | 50. | 56,20 | +1,08 | 27 | |||
| 8. | 28. | 6,6580 | -1,42 | 25 |
Feedback
CPEX verdient bereits gutes geld mit Testim (Potenzgel) das fast Weltweit Zugelassen ist .Nächster kandidat befindet sich in Phase 3 und ein weiteres für die behandlung von Diabetes in Phase 2 .
Tolle Firma gute Produkte = Aussichtsreiches Investment !
Cpex Pharma (CPEX)
Marktkap : 23,4 Mio$
Cash : 14,8 Mio$
Kurs : 9,27 $
Shares Out : 2,53 M
Pipeline
http://www.cpexpharm.com/pipeline.htm
Insider
http://finance.yahoo.com/q/it?s=CPEX
Third-Quarter Highlights
For the third quarter of 2009 compared to the third quarter of 2008;
* Revenues increased 26% to $5.0 million from $3.9 million.
* Operating expenses increased 17% to $5.8 million from $5.0 million.
* Net loss was $872,000, or $0.34 per share, compared to $1.0 million, or $0.43 per share.
The growth in revenues for the third quarter of 2009 was due to increased royalties on sales of Testim®. This growth is due to a reported 17% increase in prescriptions for Testim during the third quarter of 2009 compared to the same period in 2008. Operating expenses in the third quarter of 2009 increased $853,000, primarily due to clinical trial expenses associated with CPEX’s ongoing NasulinTM clinical program and legal costs associated with its on-going litigation with Upsher-Smith Laboratories regarding Testim. These increases were partially offset by a decrease in share-based compensation expense. Operating expenses for the three months ended September 30, 2008 include a $1.2 million non-cash charge resulting from the modification of equity awards associated with the spin-off from Bentley.
Business Update
Ongoing Clinical Trials: CPEX’s intranasal insulin product candidate for the treatment of hyperglycemia in patients with Type 1 and Type 2 diabetes, Nasulin, is continuing clinical trials evaluating the safety and efficacy profile of the product. CPEX has completed screening activities in a Phase 2a study designed to assess the efficacy and safety of Nasulin versus placebo over a 6-week treatment period. This study is being conducted at multiple centers in the U.S. Prior trials in patients with Type 1 or 2 diabetes, as well as in healthy volunteers, have indicated that Nasulin appears to have an ultra-rapid time/action profile which has the potential to mimic more closely the body’s natural insulin response to meals.
Partnering Update: Following the completion of an End-of-Phase-2 meeting earlier this year, Serenity Pharmaceuticals, CPEX’s licensing and development partner, recently began recruiting patients in multiple Phase 3 clinical trials with their undisclosed urology drug delivered using CPEX’s intranasal technology for the treatment of nocturia. These randomized, double blind, placebo controlled studies are being conducted at multiple sites in the United States.
New Patents Issued: On October 27, 2009 the United States Patent and Trademark Office issued six additional patents that expand the scope and claims of CPEX’s original patent covering Testim®, 1% testosterone gel. Testim® is marketed by Auxilium under license from CPEX. The new patents will expire in April 2023 and are listed in Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), published by the U.S. Food and Drug Administration.
Management Comments
“We are pleased about the recent completion of screening activities in our current Phase 2a study and the continued progress of our Nasulin clinical program. We look forward to presenting data from our earlier trials at the Ninth Annual Diabetes Technology Meeting taking place this week in San Francisco” stated John A. Sedor, CPEX President and Chief Executive Officer. “We are also encouraged by Serenity’s advancement of their compound for the treatment of nocturia into Phase 3 studies. This drug addresses a large urology indication with few treatment options. This is an exciting opportunity for CPEX and Serenity and we look forward to updating you on the future of this program.”
Tolle Firma gute Produkte = Aussichtsreiches Investment !
Cpex Pharma (CPEX)
Marktkap : 23,4 Mio$
Cash : 14,8 Mio$
Kurs : 9,27 $
Shares Out : 2,53 M
Pipeline
http://www.cpexpharm.com/pipeline.htm
Insider
http://finance.yahoo.com/q/it?s=CPEX
Third-Quarter Highlights
For the third quarter of 2009 compared to the third quarter of 2008;
* Revenues increased 26% to $5.0 million from $3.9 million.
* Operating expenses increased 17% to $5.8 million from $5.0 million.
* Net loss was $872,000, or $0.34 per share, compared to $1.0 million, or $0.43 per share.
The growth in revenues for the third quarter of 2009 was due to increased royalties on sales of Testim®. This growth is due to a reported 17% increase in prescriptions for Testim during the third quarter of 2009 compared to the same period in 2008. Operating expenses in the third quarter of 2009 increased $853,000, primarily due to clinical trial expenses associated with CPEX’s ongoing NasulinTM clinical program and legal costs associated with its on-going litigation with Upsher-Smith Laboratories regarding Testim. These increases were partially offset by a decrease in share-based compensation expense. Operating expenses for the three months ended September 30, 2008 include a $1.2 million non-cash charge resulting from the modification of equity awards associated with the spin-off from Bentley.
Business Update
Ongoing Clinical Trials: CPEX’s intranasal insulin product candidate for the treatment of hyperglycemia in patients with Type 1 and Type 2 diabetes, Nasulin, is continuing clinical trials evaluating the safety and efficacy profile of the product. CPEX has completed screening activities in a Phase 2a study designed to assess the efficacy and safety of Nasulin versus placebo over a 6-week treatment period. This study is being conducted at multiple centers in the U.S. Prior trials in patients with Type 1 or 2 diabetes, as well as in healthy volunteers, have indicated that Nasulin appears to have an ultra-rapid time/action profile which has the potential to mimic more closely the body’s natural insulin response to meals.
Partnering Update: Following the completion of an End-of-Phase-2 meeting earlier this year, Serenity Pharmaceuticals, CPEX’s licensing and development partner, recently began recruiting patients in multiple Phase 3 clinical trials with their undisclosed urology drug delivered using CPEX’s intranasal technology for the treatment of nocturia. These randomized, double blind, placebo controlled studies are being conducted at multiple sites in the United States.
New Patents Issued: On October 27, 2009 the United States Patent and Trademark Office issued six additional patents that expand the scope and claims of CPEX’s original patent covering Testim®, 1% testosterone gel. Testim® is marketed by Auxilium under license from CPEX. The new patents will expire in April 2023 and are listed in Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), published by the U.S. Food and Drug Administration.
Management Comments
“We are pleased about the recent completion of screening activities in our current Phase 2a study and the continued progress of our Nasulin clinical program. We look forward to presenting data from our earlier trials at the Ninth Annual Diabetes Technology Meeting taking place this week in San Francisco” stated John A. Sedor, CPEX President and Chief Executive Officer. “We are also encouraged by Serenity’s advancement of their compound for the treatment of nocturia into Phase 3 studies. This drug addresses a large urology indication with few treatment options. This is an exciting opportunity for CPEX and Serenity and we look forward to updating you on the future of this program.”
In dieser Woche findet die "Ninth Annual Diabetes Technology Meeting " statt dort präsentiert CPEX einige Daten davon könnte die Aktie profitieren . Nasulin hat Blockbuster Potential und ist noch Partner .
“We are pleased about the recent completion of screening activities in our current Phase 2a study and the continued progress of our Nasulin clinical program. We look forward to presenting data from our earlier trials at the Ninth Annual Diabetes Technology Meeting taking place this week in San Francisco” stated John A. Sedor, CPEX President and Chief Executive Officer
“We are pleased about the recent completion of screening activities in our current Phase 2a study and the continued progress of our Nasulin clinical program. We look forward to presenting data from our earlier trials at the Ninth Annual Diabetes Technology Meeting taking place this week in San Francisco” stated John A. Sedor, CPEX President and Chief Executive Officer
Antwort auf Beitrag Nr.: 38.322.738 von BrauchGeld am 04.11.09 22:04:05Nasulin hat Blockbuster Potential und ist noch ohnePartner
Antwort auf Beitrag Nr.: 38.322.767 von BrauchGeld am 04.11.09 22:07:07momentan wird noch gar nichts verdient...was nicht heist dass die niemals was verdienen
Revenues increased 26% to $5.0 million from $3.9 million.
Operating expenses increased 17% to $5.8 million from $5.0 million.
Net loss was $872,000, or $0.34 per share, compared to $1.0 million, or $0.43 per share.
Revenues increased 26% to $5.0 million from $3.9 million.
Operating expenses increased 17% to $5.8 million from $5.0 million.
Net loss was $872,000, or $0.34 per share, compared to $1.0 million, or $0.43 per share.
An nasalem/inhalierbarem Insulin haben sich schon andere versucht, weiß grad nicht welcher Großkonzern, aber das Ding ging nach hinten los, viel zu viel Insulin benötigt i.Vgl. zur Injektion unter die Haut. Außerdem gabs Sicherheitsbedenken.
Ich persönlich glaube nicht, daß da was relevant großes draus wird. Und Testosteronprodukte hauen mich auch nicht grad vom Hocker, die Umsätze sind ja überschaubar. Ich würde nicht bei der Company anheuern.
Ich persönlich glaube nicht, daß da was relevant großes draus wird. Und Testosteronprodukte hauen mich auch nicht grad vom Hocker, die Umsätze sind ja überschaubar. Ich würde nicht bei der Company anheuern.
Trading Spotlight
@Twice_Trader
Ich hab geschrieben das die gutes geld mit Testim verdienen und nicht das die schon Profitabel sind !!!!
Schau dir die Umsatzsteigerung an es wird sowieso nicht mehr lange dauern .
@traumstrand
Nur weil andere versagt haben heißt es noch lange nicht das CPEX auch scheitert bestes beispiel ist HGSI .
Für mich ist CPEX ein klarer Kauf ..WARUM ?
1. Marktkap nur winzige 23 Mio$
2. Umsatz schon jetzt ca 20 Mio US$ pro Jahr tendenz steigend
3. Insider sind auf der Käuferseite
4. Gut abgesichert mit 14 Mio$ Cash
Ich denke du weißt einfach nicht was billig und gut ist !
Warte nur bis die Aktie entdeckt wird
Ich hab geschrieben das die gutes geld mit Testim verdienen und nicht das die schon Profitabel sind !!!!
Schau dir die Umsatzsteigerung an es wird sowieso nicht mehr lange dauern .
@traumstrand
Nur weil andere versagt haben heißt es noch lange nicht das CPEX auch scheitert bestes beispiel ist HGSI .
Für mich ist CPEX ein klarer Kauf ..WARUM ?
1. Marktkap nur winzige 23 Mio$
2. Umsatz schon jetzt ca 20 Mio US$ pro Jahr tendenz steigend
3. Insider sind auf der Käuferseite
4. Gut abgesichert mit 14 Mio$ Cash
Ich denke du weißt einfach nicht was billig und gut ist !
Warte nur bis die Aktie entdeckt wird
Aktien, für die geworben werden muss, sind nix.
Antwort auf Beitrag Nr.: 38.324.884 von raceglider am 05.11.09 10:39:01Aktien, für die geworben werden muss, sind nix.
Dann hast du wohl keine ahnung von Börse ...
Dann hast du wohl keine ahnung von Börse ...
Antwort auf Beitrag Nr.: 38.326.303 von BrauchGeld am 05.11.09 13:26:31Dafür war ich immerhin bei der Telekom nicht dabei.
Antwort auf Beitrag Nr.: 38.328.042 von raceglider am 05.11.09 16:38:58Immerhin etwas positives ....
CPEX's Nasulin Insulin Therapy Featured in an Oral Presentation and Four Abstracts at the Ninth Annual Diabetes Technology Meeting
* Press Release
* Source: CPEX Pharmaceuticals, Inc.
* On 9:51 am EST, Thursday November 5, 2009
EXETER, N.H.--(BUSINESS WIRE)--CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX - News) today announced that its intranasal insulin product candidate, NasulinTM, will be featured in an oral presentation and four abstracts at the Ninth Annual Diabetes Technology Meeting, November 5-7, 2009 at the Hyatt Regency Airport in San Francisco, California. Dr. Lance Berman, Senior Vice President and Chief Medical Officer, is scheduled to deliver an oral presentation entitled “The Technology and Clinical Aspects of Nasal Insulin Therapy” at 9:30 a.m. PST on Saturday, November 7. Further details on the abstracts are provided below.
A Randomized 6-Way Crossover Study of NasulinTM, Saline and Lispro in Subjects with Type 2 Diabetes to Determine Optimum Dose Timing
A similar glucose-lowering effect may be achieved by administering Nasulin either just before or at the end of the meal offering more flexibility of dosing than with injectable insulins.
Two Randomized Crossover Glucose Clamp Studies of NasulinTM and Lispro
In both Type1 diabetic patients and healthy volunteers, peak glucose metabolism rates occurred earlier with ultra-rapid acting Nasulin than with rapid acting lispro. The pharmacodynamic profile indicates Nasulin has optimum activity when glucose levels rise during a meal with less potential for hypoglycemia in the hours after the meal has ended.
Dose-Exposure for Single and Dual Nostril Administration of Nasal Insulin (NasulinTM)
The findings from this study demonstrated significantly enhanced insulin absorption when a 50 IU dose is administered as 2 sprays of 25 IU given in the same nostril rather than one spray in each nostril. In addition, the study also demonstrated that nasal administration of up to 200 microliters per nostril was well tolerated allowing the administration of doses up to 100 IU. Together these findings provide an improved dosing methodology and a higher maximum dose for evaluation in future clinical trials.
Dose-Exposure for Two Dose Strengths of Nasal Insulin (NasulinTM)
These data demonstrated that the original Nasulin concentration (1.0%) and the new concentration (0.7%) revealed proportional dose-dependent increases in insulin exposures.
Dr. Berman commented, “The data from these studies provide important information on Nasulin’s ability to rapidly lower glucose following a meal. With the completion of each study, we gain additional insight into the potential benefits Nasulin could offer to patients with diabetes. The most exciting aspect of these results is the second dose concentration, which will provide subjects in future clinical trials with a wider dose range to individually titrate their insulin needs to maximize glucose reduction without increasing the risk of hypoglycemia. These potential advantages of Nasulin’s ultra-rapid time-action profile may provide treating physicians and their patients safer alternatives for controlling their diabetes.”
....CPEX's Nasulin Insulin Therapy Featured in an Oral Presentation and Four Abstracts at the Ninth Annual Diabetes Technology Meeting
* Press Release
* Source: CPEX Pharmaceuticals, Inc.
* On 9:51 am EST, Thursday November 5, 2009
EXETER, N.H.--(BUSINESS WIRE)--CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX - News) today announced that its intranasal insulin product candidate, NasulinTM, will be featured in an oral presentation and four abstracts at the Ninth Annual Diabetes Technology Meeting, November 5-7, 2009 at the Hyatt Regency Airport in San Francisco, California. Dr. Lance Berman, Senior Vice President and Chief Medical Officer, is scheduled to deliver an oral presentation entitled “The Technology and Clinical Aspects of Nasal Insulin Therapy” at 9:30 a.m. PST on Saturday, November 7. Further details on the abstracts are provided below.
A Randomized 6-Way Crossover Study of NasulinTM, Saline and Lispro in Subjects with Type 2 Diabetes to Determine Optimum Dose Timing
A similar glucose-lowering effect may be achieved by administering Nasulin either just before or at the end of the meal offering more flexibility of dosing than with injectable insulins.
Two Randomized Crossover Glucose Clamp Studies of NasulinTM and Lispro
In both Type1 diabetic patients and healthy volunteers, peak glucose metabolism rates occurred earlier with ultra-rapid acting Nasulin than with rapid acting lispro. The pharmacodynamic profile indicates Nasulin has optimum activity when glucose levels rise during a meal with less potential for hypoglycemia in the hours after the meal has ended.
Dose-Exposure for Single and Dual Nostril Administration of Nasal Insulin (NasulinTM)
The findings from this study demonstrated significantly enhanced insulin absorption when a 50 IU dose is administered as 2 sprays of 25 IU given in the same nostril rather than one spray in each nostril. In addition, the study also demonstrated that nasal administration of up to 200 microliters per nostril was well tolerated allowing the administration of doses up to 100 IU. Together these findings provide an improved dosing methodology and a higher maximum dose for evaluation in future clinical trials.
Dose-Exposure for Two Dose Strengths of Nasal Insulin (NasulinTM)
These data demonstrated that the original Nasulin concentration (1.0%) and the new concentration (0.7%) revealed proportional dose-dependent increases in insulin exposures.
Dr. Berman commented, “The data from these studies provide important information on Nasulin’s ability to rapidly lower glucose following a meal. With the completion of each study, we gain additional insight into the potential benefits Nasulin could offer to patients with diabetes. The most exciting aspect of these results is the second dose concentration, which will provide subjects in future clinical trials with a wider dose range to individually titrate their insulin needs to maximize glucose reduction without increasing the risk of hypoglycemia. These potential advantages of Nasulin’s ultra-rapid time-action profile may provide treating physicians and their patients safer alternatives for controlling their diabetes.”
Fact Sheet:
http://www.cpexpharm.com/files/pdfs/fs/factsheet.pdf
Gabelli & Co. initiates coverage on CPEX Pharmaceuticals, Inc (Nasdaq: CPEX) with a Buy. Price target $17.
Zacks #1 Rank Additions for Thursday
Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:
# 3PAR Inc (PAR - Snapshot Report)
# American Medical Systems Holdings Inc (AMMD - Analyst Report)
# Ameristar Casinos Inc (ASCA - Snapshot Report)
# Ashland Inc (ASH - Snapshot Report)
# Bank Mutual Corp (BKMU - Snapshot Report)
# BigBand Networks Inc (BBND - Snapshot Report)
# Capitol Federal Financial (CFFN - Snapshot Report)
# Central Garden & Pet Co (CENT - Analyst Report)
# CGI Group Inc (GIB - Snapshot Report)
# Conexant Systems Inc (CNXT - Snapshot Report)
# CPEX Pharmaceuticals Inc (CPEX) <<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
http://www.cpexpharm.com/files/pdfs/fs/factsheet.pdf
Gabelli & Co. initiates coverage on CPEX Pharmaceuticals, Inc (Nasdaq: CPEX) with a Buy. Price target $17.
Zacks #1 Rank Additions for Thursday
Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:
# 3PAR Inc (PAR - Snapshot Report)
# American Medical Systems Holdings Inc (AMMD - Analyst Report)
# Ameristar Casinos Inc (ASCA - Snapshot Report)
# Ashland Inc (ASH - Snapshot Report)
# Bank Mutual Corp (BKMU - Snapshot Report)
# BigBand Networks Inc (BBND - Snapshot Report)
# Capitol Federal Financial (CFFN - Snapshot Report)
# Central Garden & Pet Co (CENT - Analyst Report)
# CGI Group Inc (GIB - Snapshot Report)
# Conexant Systems Inc (CNXT - Snapshot Report)
# CPEX Pharmaceuticals Inc (CPEX) <<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<
Antwort auf Beitrag Nr.: 38.343.053 von BrauchGeld am 08.11.09 13:57:20Hier kann noch einiges passieren z.b. : Partner für Nasulin und Übernahme durch AUXL oder andere möglich ...Ein Schnäppchen ist die Aktie allemal !!!
CPEX´s Insulin ist das einzige das Nasal statt per Inhalation verabreicht wird und dadurch nicht die Nebenwirkungen(z.b Lungenkrebs) hat .
Pfizer,Novo Nordisk und Eli Lilly alle sind mit Inhalierbares Insulin gescheitert das bedeutet hohes Potential für CPEX falls die weiteren Daten überzeugen .
Buccal Insulin Product
CPEX Pharmaceuticals, Inc.’s proprietary permeation enhancer, CPE-215®, provides skin, mouth, nose and eye membrane absorption of a variety of pharmaceuticals. CPEX has applied this technology to Nasulin™, through which insulin is absorbed via nasal mucosa. Nasulin™ is currently in Phase II clinical trials. Bentley Pharmaceuticals spun off its drug delivery business as CPEX prior to Bentley’s merger with Teva Pharmaceuticals Industries, Ltd.
MannKind Corporation’s product candidates include AFRESA®, a mealtime insulin therapy being studied for use in adult patients with type 1 and type 2 diabetes. It is a drug-device combination product which administers insulin through inhalation to the lungs. MannKind submitted an NDA to the FDA requesting approval to market AFRESA in May 2009.
Nektar Therapeutics and Pfizer terminated their collaborative development and licensing agreement for Exubera® and Nektar’s next-generation inhaled insulin product in November 2007. Exubera® was the first inhaled insulin formulation to receive FDA approval. In April 2008, Nektar announced that it had ceased all negotiations with potential partners for Exubera® and the next-general inhaled insulin product as a result of new data analysis from ongoing clinical trials conducted by Pfizer which indicated an increased risk of lung cancer in certain patients. We are not aware of any product candidates under development by Nektar that compete directly with Oral-lyn™, nor are we aware of any product currently in Pfizer’s pipeline that directly competes with Oral-lyn™.
Novo Nordisk A/S, one of the two leading manufacturers of insulin in the world, announced in May 2008 the termination of clinical testing of the pulmonary delivery system for inhaled insulin, the AERx® insulin Diabetes Management System (AERx iDMS), initially developed by Aradigm Corporation. The product was in Phase III clinical trials at the time of Novo Nordisk’s announcement.
Alkermes, Inc. and Eli Lilly and Company entered into a licensing agreement in 2001 for the development of an AIR® inhaled insulin system based upon Alkermes’ AIR® pulmonary drug delivery system for large molecule drugs to the lungs with a dry power formulation. In March 2008, Eli Lilly announced its termination of development work relating to this product.
In May 2009, Alkermes, Amylin Pharmaceuticals, Inc. and Eli Lilly and Company submitted a New Drug Application (NDA) for exenatide once weekly, an extended-release injectable formulation, to the U.S. Food and Drug Administration (FDA). The NDA was accepted for review by the FDA in July 2009. If approved, exenatide once weekly would be the first once-a-week therapy for the treatment of type 2 diabetes.
----------------------------------------------------------------
Pfizer,Novo Nordisk und Eli Lilly alle sind mit Inhalierbares Insulin gescheitert das bedeutet hohes Potential für CPEX falls die weiteren Daten überzeugen .
Buccal Insulin Product
CPEX Pharmaceuticals, Inc.’s proprietary permeation enhancer, CPE-215®, provides skin, mouth, nose and eye membrane absorption of a variety of pharmaceuticals. CPEX has applied this technology to Nasulin™, through which insulin is absorbed via nasal mucosa. Nasulin™ is currently in Phase II clinical trials. Bentley Pharmaceuticals spun off its drug delivery business as CPEX prior to Bentley’s merger with Teva Pharmaceuticals Industries, Ltd.
MannKind Corporation’s product candidates include AFRESA®, a mealtime insulin therapy being studied for use in adult patients with type 1 and type 2 diabetes. It is a drug-device combination product which administers insulin through inhalation to the lungs. MannKind submitted an NDA to the FDA requesting approval to market AFRESA in May 2009.
Nektar Therapeutics and Pfizer terminated their collaborative development and licensing agreement for Exubera® and Nektar’s next-generation inhaled insulin product in November 2007. Exubera® was the first inhaled insulin formulation to receive FDA approval. In April 2008, Nektar announced that it had ceased all negotiations with potential partners for Exubera® and the next-general inhaled insulin product as a result of new data analysis from ongoing clinical trials conducted by Pfizer which indicated an increased risk of lung cancer in certain patients. We are not aware of any product candidates under development by Nektar that compete directly with Oral-lyn™, nor are we aware of any product currently in Pfizer’s pipeline that directly competes with Oral-lyn™.
Novo Nordisk A/S, one of the two leading manufacturers of insulin in the world, announced in May 2008 the termination of clinical testing of the pulmonary delivery system for inhaled insulin, the AERx® insulin Diabetes Management System (AERx iDMS), initially developed by Aradigm Corporation. The product was in Phase III clinical trials at the time of Novo Nordisk’s announcement.
Alkermes, Inc. and Eli Lilly and Company entered into a licensing agreement in 2001 for the development of an AIR® inhaled insulin system based upon Alkermes’ AIR® pulmonary drug delivery system for large molecule drugs to the lungs with a dry power formulation. In March 2008, Eli Lilly announced its termination of development work relating to this product.
In May 2009, Alkermes, Amylin Pharmaceuticals, Inc. and Eli Lilly and Company submitted a New Drug Application (NDA) for exenatide once weekly, an extended-release injectable formulation, to the U.S. Food and Drug Administration (FDA). The NDA was accepted for review by the FDA in July 2009. If approved, exenatide once weekly would be the first once-a-week therapy for the treatment of type 2 diabetes.
----------------------------------------------------------------
Langsam aber sicher erkennen einige das Potential ..
Da hat jemand für über 100.000 Dollar CPEX gekauft und damit die Aktie in die Höhe getrieben ...
Neues Jahreshoch ist in sicht ...............
Marktkap aktuell 28,2 Mio$ <<< noch sehrrrrr viel Potential vorhanden
Der höchste Schlusskurs Der CPEX-Aktie in diesem Jahr !!!
12,15$
12,15$
Neues 52W Hoch ...Aktie ist weiterhin massivst unterbewertet !!
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 215 | ||
| 196 | ||
| 192 | ||
| 59 | ||
| 36 | ||
| 28 | ||
| 27 | ||
| 25 | ||
| 24 | ||
| 24 |
| Wertpapier | Beiträge | |
|---|---|---|
| 23 | ||
| 22 | ||
| 21 | ||
| 21 | ||
| 20 | ||
| 20 | ||
| 20 | ||
| 19 | ||
| 18 | ||
| 18 |
